Advertisement

World Journal of Urology

, Volume 1, Issue 3, pp 180–185 | Cite as

Clinical experience with sodium cellulose phosphate

  • Charles Y. C. Pak
  • Michael J. Nicar
  • Faye Britton
Article

Summary

There is currently no treatment program which is capable of correcting the basic abnormality of absorptive hypercalciuria, although several drugs are available which have been shown to restore normal calcium excretion. Sodium cellulose phosphate best meets the criteria for optimum therapy. When given orally, this non-absorbable ion exchange resin binds calcium and inhibits calcium absorption. However, this inhibition is caused by limiting the amount of intraluminal calcium available for absorption, and not by correcting the basic disturbance in calcium transport. The above mode of action accounts for the two potential complications of sodium cellulose phosphate therapy. First, the treatment may cause magnesium depletion by binding dietary magnesium as well. Second, sodium cellulose phosphate may produce secondary hyperoxaluria, by binding divalent cations in the intestinal tract, reducing divalent cation-oxalate complexation, and making more oxalate available for absorption. These complications may be overcome by oral magnesium supplementation (1.0–1.5 g magnesium gluconate twice/day, separately from sodium cellulose phosphate) and moderate dietary restriction of oxalate. Under such circumstances, sodium cellulose phosphate at a dosage of 10–15 g/d (given with meals) has been shown to lower urinary calcium, reduce urinary saturation of calcium salts and retard new stone formation, without significantly altering urinary oxalate or magnesium. When the above precautions are taken, sodium cellulose phosphate has been shown to be clinically useful in preventing new stone formation in patients with absorptive hypercalciuria.

Keywords

Oxalate Gluconate Stone Formation Calcium Salt Urinary Oxalate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pak CYC (1979) Physiological basis for absorptive and renal hypercalciurias. Am J Physiol 237:F415-F423Google Scholar
  2. 2.
    Pak CYC (1979) Clinical pharmacology of sodium cellulose phosphate. J Clin Pharmacol 19:451–457Google Scholar
  3. 3.
    Pak CYC (1973) Sodium cellulose phosphate: mechanism of action and effect on mineral metabolism. J Clin Pharmacol 13:15–27Google Scholar
  4. 4.
    Pak CYC (1981) A cautious use of sodium cellulose phosphate in the management of calcium nephrolithiasis. Invest Urol 19:187–190Google Scholar
  5. 5.
    Hayashi Y, Kaplan RA, Pak CYC (1975) Effect of sodium cellulose phosphate therapy on crystallization of calcium oxalate in urine. Metabolism 24:1273–1278Google Scholar
  6. 6.
    Pak CYC, Delea CS, Bartter FC (1974) Successful treatment of recurrent nephrolithiasis (calcium stones) with cellulose phosphate. N Engl J Med 290:175–180Google Scholar
  7. 7.
    Pak CYC, Holt K (1976) Nucleation and growth of brushite and calcium oxalate in urine of stone-formers. Metabolism 25:665–673Google Scholar
  8. 8.
    Pak CYC, Galosy RA (1980) Propensity for spontaneous nucleation of calcium oxalate. Quantitative assessment by urinary FPR-APR discriminant score. Am J Med 69:681–689Google Scholar
  9. 9.
    Nicar MJ, Hill K, Pak CYC (1983) A simple technique for the assessment of the propensity for the crystallization of calcium oxalate and brushite in urine from the increment in oxalate or calcium necessary to elicit precipitation. Metabolism (in press)Google Scholar
  10. 10.
    Blacklock NJ, Macleod MA (1974) The effect of cellulose phosphate on intestinal absorption and urinary excretion of calcium. Br J Urol 46:385–392Google Scholar
  11. 11.
    Reinecke F, Burchardt P, Kallistratos G (1976) Experience with long-term prophylaxis of kidney stones. In: Fleisch H, Robertson WG, Smith LH, Vahlensieck W (eds) Urolithiasis research. Plenum Press, New York, pp 557–560Google Scholar
  12. 12.
    Pietrek J, Kokot F (1973) Treatment of patients with calcium-containing renal stones with cellulose phosphate. Br J Urol 45:136–143Google Scholar
  13. 13.
    Backman U, Danielson BG, Johansson G, Ljunghall S, Wikstrom B (1980) Treatment of recurrent calcium stone formation with cellulose phosphate. J Urol 123:9–13Google Scholar
  14. 14.
    Ettinger B (1976) Recurrent nephrolithiasis: natural history and effect of phosphate therapy. A double-blind controlled study. Am J Med 61:200–206Google Scholar
  15. 15.
    Blacklock NJ (1965) The pattern of urolithiasis in the Royal Navy Surgery Session. J R Nav Med Serv 51:99–111Google Scholar
  16. 16.
    Williams RE (1963) Long term survey of 538 patients with upper urinary stone. Br J Urol 35:416–437Google Scholar
  17. 17.
    Pak CYC, Fetner C, Townsend J, Brinkley L, Northcutt C, Barilla DE, Kadesky M, Peters P (1978) Evaluation of calcium urolithiasis in ambulatory patients. Comparison of results with those of inpatient evaluation. Am J Med 64:979–989Google Scholar
  18. 18.
    Strauss AL, Coe FL, Deutsch L, Parks JH (1982) Factors that predict relapse of calcium nephrolithiasis during treatment. Am J Med 72:17–24Google Scholar
  19. 19.
    Brannan PG, Morawski S, Pak CYC, Fordtran JS (1979) Selective jejunal hyperabsorption of calcium in absorptive hypercalciuria. Am J Med 66:425–428Google Scholar
  20. 20.
    Pak CYC (1981) Pathogenesis, consequences, and treatment of hypercalciuric states. Semin Nephrol 1:356–365Google Scholar
  21. 21.
    Pak CYC, Peters P, Hurt G, Kadesky M, Fine M, Reisman D, Splann F, Caramela C, Freeman A, Britton F, Sakhaee K, Breslau NA (1981) Is selective therapy of recurrent nephrolithiasis possible? Am J Med 71:615–622Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • Charles Y. C. Pak
    • 1
  • Michael J. Nicar
    • 1
  • Faye Britton
    • 1
  1. 1.Section of Mineral Metabolism, Southwestern Medical SchoolThe University of Texas Health Science Center at DallasDallasUSA

Personalised recommendations